share_log

金斯瑞生物科技：截至二零二三年十二月三十一日止年度之年度業績公告

GENSCRIPT BIO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

Hong Kong Stock Exchange ·  Mar 10 06:15
Summary by Moomoo AI
金斯瑞生物科技股份有限公司公佈截至2023年12月31日止年度業績，收益約為839.5百萬美元，較上一年度增加34.2%。其中，非細胞療法業務外部收益約為554.5百萬美元，增加8.9%；細胞療法業務外部收益約為285.0百萬美元，增加144.2%。毛利約為409.6百萬美元，增加34.7%。經調整淨虧損收窄至約298.2百萬美元，公司擁有人應佔虧損減少至約95.5百萬美元。本集團將繼續投資於細胞及基因療法（CGT）相關服務及產品，並通過數字化轉型及精益管理系統提高運營效率。董事會不建議派發末期股息，以保留資源作業務發展。
金斯瑞生物科技股份有限公司公佈截至2023年12月31日止年度業績，收益約為839.5百萬美元，較上一年度增加34.2%。其中，非細胞療法業務外部收益約為554.5百萬美元，增加8.9%；細胞療法業務外部收益約為285.0百萬美元，增加144.2%。毛利約為409.6百萬美元，增加34.7%。經調整淨虧損收窄至約298.2百萬美元，公司擁有人應佔虧損減少至約95.5百萬美元。本集團將繼續投資於細胞及基因療法（CGT）相關服務及產品，並通過數字化轉型及精益管理系統提高運營效率。董事會不建議派發末期股息，以保留資源作業務發展。
KINGSLEY BIOTECHNOLOGY CO., LTD. ANNOUNCED RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023, WITH REVENUES OF APPROXIMATELY $839.5 MILLION, AN INCREASE OF 34.2% OVER THE PREVIOUS YEAR. Of these, external revenue from the non-cellular therapeutics business was approximately $554.5 million, an increase of 8.9%; external revenue of the cell therapy business was approximately $285.0 million, an increase of 144.2%. Gross profit was approximately $409.6 million, an increase of 34.7%. Adjusted net loss narrowed to approximately $298.2 million, the loss attributable to the owners of the company decreased to approximately $95.5 million. The Group will continue to invest in cellular and gene therapy (CGT) related services and products and improve operational efficiency through digital transformation and streamlined management systems. The Board of Directors does not recommend the distribution of a final dividend to preserve the development of the Resource Operations business.
KINGSLEY BIOTECHNOLOGY CO., LTD. ANNOUNCED RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023, WITH REVENUES OF APPROXIMATELY $839.5 MILLION, AN INCREASE OF 34.2% OVER THE PREVIOUS YEAR. Of these, external revenue from the non-cellular therapeutics business was approximately $554.5 million, an increase of 8.9%; external revenue of the cell therapy business was approximately $285.0 million, an increase of 144.2%. Gross profit was approximately $409.6 million, an increase of 34.7%. Adjusted net loss narrowed to approximately $298.2 million, the loss attributable to the owners of the company decreased to approximately $95.5 million. The Group will continue to invest in cellular and gene therapy (CGT) related services and products and improve operational efficiency through digital transformation and streamlined management systems. The Board of Directors does not recommend the distribution of a final dividend to preserve the development of the Resource Operations business.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more